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Abstract: This work is devoted to modeling gastrointestinal stromal tumor (GIST) metastases
to the liver, their growth and resistance to therapies. More precisely, resistance to two standard
treatments based on tyrosine kinase inhibitors (imatinib and sunitinib) is observed clinically. Using
observations from medical images, we build a spatial model consisting in a set of nonlinear partial
differential equations. After calibration of its parameters with clinical data, this model reproduces
qualitatively and quantitatively the spatial tumor evolution of one specific patient. Important
features of the growth such as the appearance of spatial heterogeneities and the therapeutical failures
may be explained by our model. We then investigate numerically the possibility of optimizing
the treatment in terms of progression free survival time and minimum tumor size reachable by
varying the dose of the first treatment. We find that according to our model, the progression free
survival time reaches a plateau with respect to this dose. We also demonstrate numerically that the
spatial structure of the tumor may provide much more insights on the cancer cell activities than
the standard RECIST criteria, which only consists in the measurement of the tumor diameter.
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Modélisation spatiale de résistance aux traitements tumoraux :
cas des métastases hepatiques de GIST
Résumé : Ce travail est consacré à la modélisation de la croissance et de la résistance aux thérapies de
métastases hépatiques en provenance du stroma gastrointestinal (GIST). Plus précisément, la résistance
à deux traitements standard à base d’inhibiteur de tyrosine kinase (imatinib et sunitinib) est observée
cliniquement. En utilisant les observations provenant des images médiacles, nous construisons un modèle
spatial qui est un système non linéaire d’equation aux dérivées partielles. AprÃ¨s calibration des
paramètres avec les données cliniques, le modèle reproduit qualitativement et quantitativement l’évolution
spatiale de la tumeur pour un patient spécifique. D’importantes caractéristiques de la croissance, comme
l’apparition d’hétérogénéités spatiales ou les échecs thérapeutiques, peuvent être expliquées par notre
modèle. Nous avons ensuite étudié numériquement la possibilité d’optimiser le traitement en termes de
survie en progression libre et de taille minimale atteinte, en faisant varier la dose du premier traitement.
Selon notre modèle, le temps de survie en progression libre atteint un plateau en fonction de la dose.
Nous démontrons également numériquement que la structure spatiale de la tumeur pourrait fournir plus
d’informations sur l’activité des cellules cancéreuse que le critère RECIST standard qui consiste seulement
en la mesure du diamètre de la tumeur.
Mots-clés : modélisation mathématique, simulations numŕiques, GIST, métastases, rśistance et rechute
aux traitements
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1 Introduction
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal
tract, with an incidence of 9-14 cases per million people per year (see [16]). In 25% of cases (see [11]),
this type of cancer spreads to the liver. Even though GISTs resist to most of conventional cancer
chemotherapies, the discovery of activating mutations of the KIT as well as the role of PDGFR and the
new subsequent therapeutic development have revolutionized GISTs treatments. Thanks to the availability
of these highly active targeted therapeutic agents, GISTs have become typical models of personalized
treatment of cancer [6]. In particular, the survival of patients with GIST has been improved with the use
of tyrosine kinase inhibitors such as imatinib in first-line setting and a multi-targeted receptor tyrosine
kinase inhibitor, such as sunitinib or sorafenib, that inhibits PDGFRs, VEGFRs and KIT, as second-line
treatment. However several limitations in terms of diagnosis and outcomes still remain.
First, an important variability exists in the molecular and genetic characteristics that drive the
pathogenesis of these tumors. Hirota et al. have proved that molecular alterations in KIT gene with
gain-of-function mutations occurred in these tumors (see [12]). Moreover, in addition to the primary
mutation, secondary mutations have been identified in patients with advanced GIST pretreated with
tyrosine kinase inhibitor. At this time, 10 different molecular subsets of GIST with different molecular
alterations have been reported. For patients with KIT mutations, an imatinib resistance is frequently
observed, as reported in [5]. For other patients, imatinib controls the metastatic disease during a more or
less long period, around 20-24 months in 85% of cases. Physicians have then to switch to another molecule
or use an alternative therapy. Since the prognosis and the sensitivity to the targeted treatments have
been reported to be patient-dependent, we aim at developing a patient-dependent mathematical model
based on medical images of liver metastases. We focus on locally advanced GIST in order to determine,
for each patient, the time of emergence of mutations in cancer cells, the relapse times after the first-line
and the second-line treatments, as well as the geometric features of tumor growth.
Second, the new anticancer agents with targeted mechanisms of action as used for the treatment of
GIST have demonstrated the inherent limitation and unsuitability of the usual anatomic tumor evaluation,
that only considers the largest diameter of the lesion (i.e. the RECIST criteria, see [20]). For clinicians,
the challenge consists in optimizing these cancer treatments and in particular to determine the more
adequate time to switch from the first-line to the second-line treatment, in order to increase the overall
survival. The estimate of the relapse time is therefore crucial.
Clinical follow-up to monitor the disease evolution is mainly performed with CT-scans. We emphasize
that the effect of these new drugs changes the paradigm according to which the tumor sensitivity to
the treatment is measured (see [19]), since CT-scans have reported other information such as tumor
heterogeneity: the RECIST criteria seems no more sufficient.
The aim of this work is to provide a spatial model of standard treated GISTs in order to compare the
model with the images, and possibly to highlight the peculiarities of the tumor growth or regrowth. It is
worth noting that this paper is a first step in the modeling of tumor drug resistance based on clinical
images.
We provide a model, which consists in a non-linear system of partial differential equations (PDEs),
in order to account for the spatial aspect of the tumor growth. Actually, the models based on ordinary
differential equations (ODEs) as the models of Mendelsohn, Gompertz or Bertalanffy make it possible to
track the tumor area growth but they do not consider the spatial aspects of the growth. We refer to the
review by Benzekry et al. for more details on such 1D models [3] Our model is derived in the same vein as
Ribba et al. [17] – we also refer to [9,10] – in order to describe the evolution of the disease. The main novelty
of the model lies in the description of the treatments. Two treatments are considered: the first treatment
consists in a cytotoxic effect while the second-line treatment has both cytotoxic and anti-angiogenic effects.
3 different proliferative cells are used to describe the resistance to the treatment: one cell population is
sensitive to the two treatments, another one is only sensitive to the second treatment while the third
cell population is resistant to both treatments. We also provide a simple model of angiogenesis, which is
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crucial in the metastasis growth.
Once the model is built, we provide an appropriate numerical scheme that makes it possible to solve the
PDEs. In particular, we present in Section 3 a new WENO5 type scheme that stabilizes the computation
by using a combination of the classical WENO5 stencil and a twisted stencil. We then extensively compare
our model to the clinical data of one specific patient, for whom we have the whole clinical protocol, in
Section 4. Let us mention that it has been necessary to introduce a numerical reconstitution of the
CT-scan from the numerical results, in order to compare the grey-levels of CT-scans with our simulations.
Once the fitting has been obtained, we then investigate numerically the effect of the treatment dose on the
tumor growth progression. The counter-intuitive result lies in the fact that according to the parameters
we use for the fitting with the data, the increase of the dose of the first treatment does not improve
the progression free survival rate. This result is explained in subsection 4.2.2. We then conclude on the
consistency of our model by presenting the different behaviors of the tumor evolution that can be obtained.
We also fit the numerical tumor area with another patient, whose tumor is close to the liver boundary. It
is worth noting that for such patients, the shape of the tumor cannot be recovered. Our model does not
take the corresponding mechanical constraints into account. However, the tumor area seems to be well
reproduced by our simulations.
Main Insights
On the left part of Figure 1 we provide the sequence of the CT-scans, and on the right part we give the
tumor area evolution of the GIST liver metastasis of one specific patient called patient A. On each CT-scan
of patient A, we have depicted the darkest region, which corresponds mainly to the necrotic cells. During
the tumor evolution, one can see that the heterogeneity of the tumor changes (for instance in Figure 1b
the tumor is homogeneous while in Figure 1f is heterogeneous). We distinguish in the tumor area evolution
the points corresponding to a homogeneous tumor (in fulfilled circle) from the point corresponding to
heterogeneous tumor.
Interestingly, just before the tumor regrowth at Day 776 (Figure 1c) and Day 1116 (Figure 1f), one can
see on the tumor a rim clearer than the dark core, while the response to the treatment is followed by a dark-
ening of the tumor (see Figure 1b and 1e). Such successive stages of tumor homogeneities/heterogeneities,
are particularly pronounced in GIST liver metastases, and our goal is to provide an explanation of such
behavior.
The first results of this paper lies in the fact that it makes it possible to describe the tumor evolution in
terms of tumor area compared with the CT-scans measurements, as presented by Figure 1g: the continuous
line corresponds to the numerical results. It is worth noting that we do not provide a 1D-model that
describes the tumor volume. We deal with a complex non-linear PDE model, which is phenomenological
and which describes the behaviour of cancer cells with respect to the space and the time variables.
Therefore this first fit with the tumor area is a non trivial insight.
The second main insight is that our model brings new information on the tumor structure, that seems
corroborated with the CT-scans. Actually, as it will be presented in the following, we link the tumor
heterogeneity to an increase in the cellular activity, meaning that a resistant phenotype is emerging in the
clearer region. According to our modeling, such a behavior can be seen before the treatment failure, while
RECIST criteria has not changed. For instance in Figure 2, we compare the structure of the tumor at two
different days: the heterogeneity of the tumors seems to be well captured by the numerical simulations.
Therefore our paper can be seen as a first step in developing new tools to evaluate the tumor response to
treatement based on tyrosine kinase inhibitors.
Inria
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(a) Sept 16, 2008 –
Day 119
(b) June 30, 2009 –
Day 406
(c) July 5, 2010 –
Day 776
(d) Oct 25, 2010 –
Day 888
(e) Jan 7, 2011 –
Day 962
(f) June 10, 2011 –
Day 1116
(g) Tumor area. Each point represents the tumor area measured on
CT-scans and the line stands for our numerical results.
The letter refers to the CT-scans shown on the left. The symbol ⊕
stands for heterogeneous tumor, • stands for rather homogeneous
tumor and ◦ stands for CT-scan on which it is difficult to detect
heterogeneous aspect.
The value of parameters used in the numerical simulation are given in
Table 2.
Figure 1. Spatial evolution of the liver metastasis of patient A on a series of CT-scans.
(a) Day 406 (b) Day 776
Figure 2. Comparison between CT-scans of patient A and the numerical simulations.
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2 Description of the model
Our model is a system of PDEs similar to the model of Bresch et al. [8]. Roughly speaking, the tumor is
described thanks to densities of proliferative and necrotic cancer cells denoted by P and N respectively.
Cell proliferation leads to an area increase in the tissue, which creates a pressure whose gradient transports
the surrounding healthy cells S away from the core of the tumor. The cells located at the center of the
tumor turn into a necrotic phase, because of a lack of oxygen for instance, except if angiogenesis has
occured to provide them nutrient supply. Angiogenesis and nutrient supply are taken into account with a
simplistic description similar to [4, 18]: since the vascularization drives the nutrient concentration towards
the tumor, we introduce a variable M that describes both vascularization, neovascularization and nutrients
brought to the tumor thanks to an advection-diffusion equation. We also introduce growth factor effects
through a variable ξ that modulates M . The set of quantities used in our model is resumed in Table 1.
The main novelty lies in the modeling of the treatments. Two treatments are considered (one can see
in [15], the recent works by Lorz et al. for more elaborated models on drug resistance). The first one is a
specific tyrosine kinase inhibitor, such as imatinib, that has a cytotoxic effect on proliferative cells. The
second treatment is a multitargeted kinase inhibitor, such as sunitinib or sorafenib, that has both cytotoxic
and anti-angiogenic effects, meaning that in addition to the cytotoxic effect, it blocks the production
of growth factors such as vascular endothelial growth factors (VEGF) and thus decreases the nutrient
supply brought to the tumor. It is well-known that the cytotoxic drugs do not impact similarly all the
metastatic cancer cells since resistant phenotype can appear in the proliferative cell population. Moreover
it is well-known that cancer cells can resist differently to hypoxia. Therefore we split, as in [7], the density
P of proliferative cells (P -cells) into 3 subpopulations P1, P2 and P3, such that P = P1 + P2 + P3, where
• P1 denotes the fraction of proliferative cells that are sensitive to the first-line treatment T1, based
on imatinib molecule and also to the second-line treatment T2, based on sunitinib or sorafenib, that
has both cytotoxic and antiangiogenic effect,
• P2 describes the density of proliferative cells that are resistant to the first-line treatment T1 and
sensitive to treatment T2,
• P3 stands for proliferative cells that are resistant to both treatments.
It is worth noting that we do not aim at describing the evolution of the tumor from the very begining
of the GIST cancer, but we only focus on the evolution of the metastasis located at the liver. Therefore,
according to the clinical observations, it seems relevant to consider that the three cell subpopulations are
present when the GIST metastasis is detected.
Name Meaning Unit
P1(t,x) Fraction of cells that are both sensitive to treatments T1 and T2 -
P2(t,x) Fraction of cells that are resistant to treatment T1 and sensitive to treatment T2 -
P3(t,x) Fraction of cells that are both resistant to treatments T1 and T2 -
N(t,x) Fraction of necrotic cells -
S(t,x) Fraction of healthy cells -
M(t,x) Fraction of nutrients // Vascularization -
ξ(t) Average velocity of nutrients transport in direction of the tumor cm.d−1
v(t,x) Velocity of the passive movement of the tumor under the pressure cm.d−1
Π(t,x) Medium pressure 1 kg.cm−1.d−2
Table 1. List of quantities computed by the model – d = day
1 The mass unit in the pressure Π and in the permeability k has no importance, since only k∇Π is relevant, and this
term is homogeneous to cm.d−1. Thus k and Π have just to be in the same arbitrary mass unit.
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2.1 The mathematical model
Let Ω be the domain where the tumor grows, and ∂Ω denotes its boundary. Note that the following model
is valid for tumors that never reach the boundary ∂Ω.
2.1.1 PDEs on proliferative, necrotic and healthy cells
The proliferative cell densities are driven by the following transport equations:








(1 +M)P1 in Ω, (2.1)




P2 − µ2χ2(t)(1 +M)P2 in Ω, (2.2)
∂tP3 +∇ · (vP3) = (γpp(M)− γpd(M))P3 in Ω, (2.3)
where χi(t) = 1[Tiini,Tiend[(t) is the time-characteristic functions of treatment Ti and µi stands for the rate
of the death2 due to Ti of the proliferative cells, for i ∈ {1, 2}. The term v(t,x) denotes the velocity due
to the tumor area changes and M(t,x) stands for the vascularization and the nutrient supply. The rate of















where R is a numerical smoothing parameter3, γ0 and γ1 are respectively proliferative/decay parameters
and Mth is the hypoxia threshold.
We assume that healthy cells are only sensitive to hypoxia, and they are passively transported by the
tumor area changes:
∂tS +∇ · (vS) = −γsd(M)S, (2.6)
where γsd is the rate of death of healthy cells due to hypoxia:







Note that γsd vanishes exactly if M ≥Mth in order to ensure that the S = 1 on the outer boundary at
any time. Finally, necrotic cell density satisfies
∂tN +∇ · (vN) = γpd(M)P + γsd(M)S +
(
µ1χ1(t)P1 + µ2χ2(t)(P1 + P2)
)
(1 +M)− δ(1 +M)N, (2.8)
where
P = P1 + P2 + P3, (2.9)
and δ is a parameter that controls the elimination rate of the necrotics cells by the immune system.
The following Dirichlet conditions are used on the boundary if the velocity is incoming:
P1 = P2 = P3 = N = 1− S = 0 for x ∈ ∂Ω, if v.n < 0, (2.10)
where n is the outgoing normal vector of the domain Ω.
2The death rate due to the treatment is clearly linked to the dose of drug delivered to the patient, but not only. For
instance, the sensitivity of the patient and the dose that really reaches the tumor are also involved.
3Note that the functions γpp and γpd are merely regularized Heaviside functions. For the numerical simulations, we
arbitrarily set R to 5.
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2.1.2 Mechanics
By using the following saturation condition (as in [1])
P +N + S = 1, (2.11)
and summing (2.1),(2.2),(2.3),(2.6) and (2.8), we obtain
∇ · v = γppP − δ(1 +M)N. (2.12)
Darcy’s law ensures the solvability of the the system, similarly to [17]:{
v(t,x) = −k∇Π(t,x) in Ω,
Π(t,x) = 0 on ∂Ω,
(2.13)
where Π is the pressure (or potential) of the medium and k its permeability. The homogeneous Dirichlet
condition is used since we consider that the domain of interest is not isolated, and the outer medium does
not impose a pressure on the tumor. This assumption is valid for small tumors that are not mechanically
constrained by the extratumoral region.
2.1.3 Vascularization, Nutrient Supply and Angiogenesis
It remains to describe the vascularization/nutrient supply M and the impact of treatment T2 on it. It is
worth noting that the second-line treatment does not impact directly M , but it blocks the production of
growth factors that drive the quantity M .
We thus introduce a scalar variable ξ, which is related to the mean concentration of growth factors.
It has been reported by [13] that hypoxic cells increase their production of growth factors, while highly
proliferative cells do not need additional nutrient supply. Therefore, if M is below Mth then ξ should
increase. Note also that the anti-angiogenic effect of treatment T2 decreases the production of ξ, but only
for the cells P1 and P2 since P3 is the density of cells that are sensitive neither to T1 nor to T2. We thus









(P1 + P2) + P3
)
dx− λξ. (2.14)
The dimensionless parameter ν2 ∈ (0, 1) stands for the anti-angiogenic effect of T2, assumed to be similar
for P1 and P2, while εξ reflects the ground production of growth factors by cancer cells.








− ηPM + ψ∆M in Ω,
M(t,x) = 2Mth on ∂Ω,
(2.15)
where C0 is the angiogenic capacity of healthy cells, η denotes for the destruction of the vascularization
by proliferative cells, and ψ is a diffusion parameter. The diffusive term describes the infiltration of
blood vessels into the tumor. From the numerical point of view, this term has a regularizing effect on the
vascularization M , and thus stabilizes the numerical scheme.
Note that if we have initially
0 ≤ ‖M |t=0‖L∞ ≤ 2Mth (2.16)
then at any time t, 0 ≤M(t) ≤ 2Mth. This reflects the fact that the healthy tissue surrounding the tumor
is well-vascularized and supplied with enough nutrients.
Inria
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2.2 Vector formulation of the equations on cancer cells


















γpd(M)P + γsd(M)(1− P −N) +
(
µ1χ1P1 + µ2χ2(P1 + P2)
)
(1 +M)− δ(1 +M)N
 .




Wi − δ(1 +M)W4, (2.17)
so that the set of equations (2.1)-(2.3) and (2.8) and (2.12) closed by the Darcy law read{
∂tW + (∇W).v + W(∇ · v) = G(M,W) on Ω,
W = 0 on ∂Ω, if v. n < 0,
(2.18)
and {
−∇ · (k∇Π) = F(M,W), in Ω,
Π(t,x) = 0 on ∂Ω.
(2.19)
Note that the density of healthy cells S is then given by (2.11).
3 Numerical methods
We use a 2D cartesian staggered grid with a finite volume method. For the numerical calculations, the
domain Ω is the rectangle [0, L]× [0, D]. The domain is meshed by a cartesian grid with Nx points along
the x-axis and Ny points along the y-axis.
The cancer cell densities are discretized at the center of the cell grid and the velocities are discretized
at the middle of each edge as shown in Figure 3.
(i− 12 , j)
(i, j) (i+ 12 , j)
(i, j + 12 )
(i, j − 12 )
ey
ex
P1, P2, P3, N, S,M
vx
vy
Figure 3. Discretization of unknown variables on one cell grid.
Note that the equality (2.11) gives straightforwardly S, without solving equation (2.6). We split the
computation into the following steps.
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• Given4 Wn, and Mn at the time tn, we infer Fn = F(Mn,Wn) and Gn = G(Mn,Wn).
• We first compute the pressure Πn solution to (2.19) with Fn as right hand side, from which we infer
the velocity vn thanks to the equation (2.13).
• Then the new computation time tn+1 = tn + ∆t is determined using the equation (3.17).
• Afterwards we compute Wn+1 from (2.18), from which we infer Sn+1.
• We end by computing ξn+1 and Mn+1 thanks to (2.14)–(2.15).
Let present precisely the schemes used in the numerical simulations.
3.1 Computation of pressure and velocity
According to (2.12) and (2.13), the pressure Πn is given by{
−∇ · (k∇Πn) = Fn := F(Mn,Wn) on Ω,
Πn = 0 on ∂Ω,
(3.1)
where F is defined by (2.17). We solve this equation thanks to a classical 5-points scheme. The component
along ex of the velocity v
x,n
i+1/2j at xi+1/2 j (resp. the component along ey, v
y,n
i,j+1/2 at the point xi j+1/2)




, vy,ni,j+1/2 = −k
Πni,j+1 −Πni,j
∆y
and the velocity vnij at the point xij is approached by
vnij = v
x,n




















By definition of F given by (2.17), the equation (2.12) leads to ∇ · v = F. Thus, the equation (2.18) can
read also as a non-conservative form
∂tW + (∇W).v = G(M,W)− (∇ · v)W = G(M,W)− F(M,W)W, (3.3)
solved thanks to the following time-splitting scheme
W∗ −Wn
∆t/2
= Gn − FnWn, (3.4)
W# −W∗
∆t
+ (∇W∗).vn = 0, (3.5)
Wn+1 −W#
∆t/2
= Gn − FnWn. (3.6)
A WENO5 type method as given by [14] is used to approach the gradient ∇W involved in (3.5).
4The superscript n stands for the discrete time tn of the quantity (for instance Sn is the density of healty cells at the
time tn)
Inria
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3.3 Computation of the quantities ξ and M


















where we use a standard rectangle rule to approach the integral in the right hand side.































Equation (3.9) is computed as a heat diffusion equation with a standard 5-points scheme on the grid. The
right hand side is approached by a WENO5 type scheme.
3.4 Modified WENO5 scheme
The standard WENO5 scheme as given by [14] is accurate in most of the cases, however some sets of
parameters5 make us face numerical instabilities. More precisely, starting from irrotational initial data,
the simulation can generate a clover-like structure, as reported by Figure 4, while the circular shape
should be preserved.
Note that such errors on the shape provide error on the evolution of the area of the lesion, since the
clover shape increases the contact surface and thus modifies the interaction between the vascularization
and the tumor. These instabilities have to be fixed. The problem is due to the WENO5 stencil that
tends to favor the directions of the grid where changes in the velocity direction occur. As we can see on
Figure 4d, on the center of the tumor (around x = 5 cm in Figure 4d), there is a compression point: the
velocity has centripetal directions, since vx is positive on the right and negative on the left. Moreover,
around 1.5 cm from the center of the tumor, there is a rim of proliferative cells that induce a spreading
movement: the velocity is centripetal close to the center but centrifugal far from it.
More precisely, for the standard WENO5 scheme, at any point xij of the grid, the numerical approxi-
mation Wn+1ij to equation (3.5) at the time t














where vx,ni,j and v
y,n
i,j are defined by (3.2) and where F is the WENO5 functional given by [14]. In order to
avoid the numerical instabilities, we introduce the following twin-WENO5 scheme, which is a combination
of the standard WENO5 stencil and a rotation at the angle a of the WENO5 stencil (see Figure 5), where
a is defined by the grid steps ∆x and ∆y as
a = arctan(∆y/∆x) ∈ (0, π/2).
5The set of parameters have been found incidently by fitting the tumor area evolution of patient B, see Section 5.1.
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(a) Day 0 (b) Day 543 (c) Day 1053
(d) Profile of vx along ex at Day 1053
Figure 4. Numerical simulations with the standard WENO5 stencil for the specific set of parameters.
Starting from circular initial data, clover-like structures appear.
We introduce the coefficients (vr,ni,j , v
θ,n








cos a sin a







∆x2 + ∆y2, (3.12)
and we discretize equation (3.5) thanks to our twin-WENO5 scheme:
Wn+1i,j = W
n






















where β ∈ (0, 1) is a numerical parameter that has to be chosen. In particular, the standard WENO5
scheme holds for β = 0. As we can see on Figure 6, our new scheme keeps the irrotational property in
cases where WENO5 does not.
6The coefficients vr,ni,j and v
θ,n
i,j are defined such that
vni,j = v
x,n
i,j ex + v
y,n
i,j ey = v
r,n
i,j er + v
θ,n
i,j eθ, with er = cos a ex + sin a ey , eθ = − sin a ex + cos a ey .
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∆y
∆x




Figure 5. Stencil of the twin-WENO5 scheme for a uniform grid (left) and a non-uniform grid (right).
(a) Day 0 (b) Day 543 (c) Day 1053
Figure 6. Numerical simulations with the twin-WENO5 scheme (β = 0.26). Comparing in Figure 4, the
conservation of irrotational invariance is very clearly improved.
3.5 CFL condition
In addition, CFL-type restriction condition is required to preserve numerical stability. First, the WENO5













The forward Euler scheme on equation (3.4) leads to the following inequality (coordinate by coordinate)
W∗ = Wn +
∆t
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where 1 = t(1, 1, 1, 1), the symbol ◦ stands for the Hadamard product (the pointwise product of the




n)− γpd(Mn)− (µ1χn1 + µ2χn2 )(1 +Mn)
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A similar relation between W# and Wn+1 can be read from equation (3.6). Thus, assuming that Wn ≥ 0









:= ∆tW . (3.15)
ensures that Wn+1 ≥ 0 and Sn+1 ≥ 0. Similarly, the forward Euler scheme in equation (3.7) and in










Finally, since the velocity might be very small, to prevent too large ∆t, we arbitrarily choose a velocity v̄
and our CFL condition reads7







for a given constant CCFL < 1.
4 Numerical Results
4.1 Numerical tools to compare the results with the CT-scans
In order to compare the numerical results to the CT-scans, we have to define the appropriate quantities of
interest as well as to develop a numerical tool that reproduces the grey scale.
4.1.1 Numerical determination of the tumor area, the necrotic part and the tumor mass
Let the threshold εth be the minimal fraction of tumor cells above which we define numerically the tumor.




1{x :P (t,x)+N(t,x)>εth}(x) dx. (4.1)




1{x : J(t,x)>εth}(x) dx, for J ∈ {P1, P2, P3, N}. (4.2)








P (t,x) dx. (4.4)
7In the simulations, we choose v̄ = 1 cm/month, considering 30 days in one month and CCFL = 0.4.
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4.1.2 Numerical reconstitution of CT-scans
The comparison of the numerical simulations with the CT-scans raises an important difficulty. Actually,
unlike the numerics that provide the numerical values at any point of each quantity S, P and N , the
CT-scans provide grey-levels that are related to local radiodensities thanks to the Hounsfield scale. Since
Hounsfield unit (HU) makes it possible to quantify the tumor area and to detect its location on CT-scans,
we introduce a numerical HU, which is a linear combination of the numerical results. More precisely,
we consider a linear grey scale ranging from black to white. To each species (P -cells, healthy cells and
necrotic cells), we allocate a coefficient τP , τS and τN , we then plot the quantity
τPP + τNN + τSS, (4.5)
which is a kind of numerical grey-level. Since for abdominal CT-scans, the Hounsfield scale is limited
from -200 to +200, we arbitrarily fix the above coefficients to
τP = 60, τS = 120, τN = −140,
and we set the value -200 to black color and +200 to white color.
4.2 Extensive study of one specific patient
4.2.1 Comparison of the numerical results with to clinical data
We focus on patient A for whom we have the whole clinical protocol, as well as the clinical data of
the tumor area evolution and a sequence of CT-scans. The numerical simulations are performed in a
square of side L = D = 6 cm with 120 points in each direction. The time step ∆t is computed by using
equation (3.17).
We choose the numerical parameters in order to reproduce the evolution of the tumor area. In
particular, we did not try to fit with the images, we only verify that the spatial evolution is plausible
compared to the images. The parameters are summarized in Table 2.
The numerical tumor area is then compared to the measured areas on Figure 1g (the circles represent
the real data and the solid lines represent the numerical simulation). It is worth noting that according to
this figure, the evolution of the tumor area is well reproduced. We emphasize that the initial conditions
are crucial in the tumor growth. In order to match qualitatively with the shape of the lesion at the
initial time (see Figure 1a), the initial condition is chosen as a perturbed ellipse. More precisely, given 3









e(y −D/2) + cr2
)2
, (4.6)
with x = (x, y) and where c =
2π
2π − arccos(1− 2εth)
. We then use the function Y defined by8
Y (x) =

1 if d(x) ≤ 0.5,










in order to impose the initial conditions:
P1|t=0 = (1− Σini)Y, P2|t=0 =
Σini
1 + qini
Y, P3|t=0 = qiniP2(t = 0), N |t=0 = 0,
M |t=0 = 2Mth,
(4.8)
8Note that if e = 0, then Y is rotationally invariant.
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Value for fit Value for fit
Name Meaning Unit patient A patient B
(Figure 1g) (Figure 10g)
γ0 Tumor cells growth rate d−1 2.0e-2 6.33e-3
γ1 Tumor cells apoptosis rate d−1 8.0e-3 4.46e-2
CS Healthy tissue apoptosis rate compared to γ1 - 10 10
Mth Hypoxia threshold - 2 2
δ Elimination rate of the necrotic tissue by the
immune system
d−1 1.33e-2 8.19e-2
ψ Diffusion rate of the oxygen cm2.d−1 1.33e-2 3.33e-3
η Consumption rate of tumor cells d−1 6.67e-2 8.05e-3
α Angiogenic excitability cm−1.d−2 1.11e-3 8.0e-3
λ Elimination rate of angiogenic growth factor signal d−1 2.0e-2 0.68
C0 Angiogenic capacity of healthy tissue d−1 3.33e-2 3.33e-2
k Tissue permeability kg−1.cm3.d 1 1
T1ini Beginning (in days) of the treatment T1
administration
d 119 0
T1end Ending (in days) of the treatment T1 administration d 867 845
T2ini Beginning (in days) of the treatment T2
administration
d 867 1049
T2end Ending (in days) of the treatment T2 administration d 1298 1600
µ1 Proliferative cells death rate due to treatment T1 d−1 7.17e-3 3.45e-3
ν2 Inhibition rate of the angiogenesis by treatment T2 - 0.8 0.90
µ2 Proliferative cells death rate due to treatment T2 d−1 4.27e-3 3.0e-4
εth Minimal proportion of tumor cells that can be
detected on scans – Minimal treshold for the
numerical location of the tumor
- 1.0e-2 0.1
Σini Proportion of cells that are resistant to imatinib at
the time t = 0 – Equivalent to (P2 + P3)t=0
- 3e-06 0.10
qini Proportion of imatinib resistant cells that also re-
sist to sunitinib at time t = 0 – Equivalent to
(P3/P2)t=0
- 7.5e-3 0.41
ξini Growth factor signal at time t = 0 cm.d−1 3.33e-3 0
εξ Residual production of growth factor - 0.1 0.1
L,D Dimensions of the computational domain cm 6 12
Nx, Ny Number of point for each dimension of the compu-
tational domain
- 120 132
r1 Radius along x-axis of the initial condition cm 0.47 0.5
r2 Radius along y-axis of the initial condition cm 0.36 0.5
e Kind of eccentricity of the initial condition - 0.35 0
β Twin-WENO5 weight - 0 0.3
Table 2. List of parameters of the models and their values for the two patients considered – d = day
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where Σini denotes the proportion of cells that are resistant to treatment T1 and qini is the proportion of
P2 cells that resist also to treatment T2. For patient A, we choose e = 0.35 and r1 = 0.47; r2 = 0.36.
(a) Day 119 (b) Day 409 (c) Day 778
(d) Day 870 (e) Day 961 (f) Day 1120
Figure 7. Numerical simulations for patient A: spatial evolution of the lesion with numerical
reconstitution of CT-scans.
The spatial aspects of the numerical simulations presented in Figure 7, make appear the following
facts:
i) During the phase without treatment, from Day 0 to Day 119, the tumor grows. Since necrotic and
proliferative cells are present, the numerical tumor is heterogeneous, as reported by Figure 7a.
ii) Then treatment T1 is delivered from Day 119 to Day 867. P1-cells are killed and necrotic cells become
predominant. Due to the choice of the coefficient τN , the numerical tumor becomes homogeneous
and darker as shown by Figure 7b.
iii) The rebound of the proliferative activity just before the regrowth of the tumor at Day 776 is
characterized by an increase in tumor heterogeneity: a proliferative rim appears and gradually fulfill
the necrotic interior of the tumor as illustrated by Figure 7c. It is worth noting that treatment T1 is
still delivered and thus resistant cells start to be predominant.
iv) Then treatment T2 is delivered from Day 867 to Day 1298. Once again, the necrotic population
increases, and the numerical tumor is darker, as shown by Figure 7d-7e.
v) Finally, at Day 1116, new therapeutic failure is getting ready. It is characterized once again by a
proliferative rim on the tumor boundary (see Figure 7f).
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Interestingly, the numerical spatial results are in accordance with the data, at least up to the last
relapse around Day 1000. Actually, the five steps that have been numerically observed are reported by
CT-scans (see Figure 1a-1f).
After Day 1116, our model is probably no longer valid since the numerical structure of the tumor
is very different from the CT-scan. Maybe other phenomena that are not accounted for by our model
occur, such as micro-environment changes or cell mutations. Some interactions in the 3rd direction (not
accounted for here) can be also involved.
We emphasize that the model seems to provide important information that clinicians cannot have
access to with imaging devices. More precisely, Figure 8, which presents the area and mass evolution of
each cell population, makes it possible to state that according to our model:
• During the first shrinkage of the tumor caused by treatment T1, from Day 119 to Day 406, we
observe that
i) Treatment T1 kills P1-cells that become necrotic tissue.
ii) The reduction of the area is due to the elimination of necrotic cells by the immune system.
iii) P2 and P3-cells that are not sensitive to treatment T1 keep dividing.
• During few months, from Day 406 to Day 778, the tumor area continues to slowly decrease due to
the death of P1-cells, however P2 and P3 cells keep growing and replace progressively the eliminated
necrotic cells. Even though the cellular activity of P2 and P3 is not affected by the treatment, this
leads in a first time, to a stabilization of the tumor area, before a regrowth of the tumor at Day 778.
Actually, when P2 + P3 becomes too high, the tumor growth reoccurs, governed by cells that are
resistant to treatment T1.
• During treatment T2, from Day 867 to Day 1298, we can notice that
i) P1-cells are still sensitive to the treatment.
ii) P2-cells become necrotic since they are sensitive to treatment T2.
iii) P3-cells that are resistant to the two treatments keep growing.
It is worth noting that for each relapse, the proliferative activity occurs on the tumor boundary, where
there are nutrients. Moreover, our model produces differences in the evolution of the tumor area A and
the tumor mass evolutionM given respectively by (4.1) and (4.4).
In particular, the mass of cancer cells decreases right after the drug delivery, while the tumor area
decreases with a delay in each case. This delay may be due to the fact that the killed proliferative
cells turn into the necrotic phase. Therefore the total area is still the same until the necrotic cells are
eliminated by the immune system. In addition, our model distinguishes the effect on angiogenesis of the
two treatments. In both cases the angiogenic signal decreases but for different reasons. Actually, while
treatment T2 inhibits directly the angiogenic signal, treatment T1 kills P1-cells, which implies indirectly a
decrease of the production of this signal.
4.2.2 Numerical study of the influence of treatment T1 efficacy
We focus now on the numerical study of different outcomes of treatment T1, to investigate their influence
on the tumor growth. We take the parameters of Table 2, except that we let vary µ1. Let us define two
characteristic durations:
• TPFS, which is the progression free survival time. It is the time duration for which the tumor is
smaller (in term of area) than at the beginning of the treatment.
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Figure 8. Evolution of the mass (integral of grey levels, in arbitrary unit) and area (mm2) of each
cellular population and angiogenic signal evolution (cm.d−1) given by the numerical simulations.
• Tdouble, which is the time duration for which the tumor area is below twice its initial value at the
beginning of the treatment.
Note that this study is purely theoretical and cannot be used for treatment optimization since the
whole evolution of the disease (including the relapse phase) is needed in order to obtain the parameters
that are used for the simulation. It is therefore clear that our approach, for the time being, cannot lead to
the determination of an optimal protocol, but this numerical investigation is a crucial step in addressing
this important challenge.
In Figure 9a, we show the progression free survival time TPFS with respect to µ1. If µ1 is below a
threshold value µth (µth ∼ 0.0047 for patient A), then the tumor growth is not stopped. For µ1 above this
threshold, TPFS increases rapidly and reaches a plateau, which means that it is not necessary to increase
the dose, since it has no effect on TPFS.
In Figure 9b, we provide Tdouble. As one can see, Tdouble is not increased by the increase the dose
above the threshold µth, which means once again it is not necessary to increase the drug delivery above a
certain threshold value.
In Figure 9c, we have represented the minimum size reached by the lesion with respect to the dose
µ1. Note that this curve is decreasing: therefore for high values of µ1, the minimum of the lesion area is
smaller. However, as shown in the Figure 9d, the relationship between the minimum size of the lesion
and the doubling time is not monotonic. In particular, if the minimum size of the lesion is very small,
then the doubling time can be smaller. This could be thought of as some Darwinian selection mechanism:
P1-cells, that are predominant when the lesion is detected, are killed faster by the treatment and therefore
more room and more nutrients for P2-cells are available for their growth. Thus, the control time becomes
smaller. These curves show that there exists a threshold µth above which treatment T1 is efficient. Beyond
this threshold, the minimal tumor area decreases again, but the lifetime of the patient is not increased.
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(a) Progression free survival time (TPFS in days) with
respect to µ1.
(b) Time corresponding to the growth of tumor area by a
factor 2 (Tdouble in days) with respect to µ1.
(c) Minimal area reached (Amin in mm2) with respect to
µ1.
(d) Phase portrait.
Figure 9. Efficacy of treatment µ1 for patient A. The star corresponds to the parameters used in
Figure 1 for the fit of the tumor area.
5 Discussion
In the previous section, we have extensively studied our model on one specific patient, patient A, whose
tumor lesion was followed up by a sequence of CT-scans. We found parameters that make it possible to
compare qualitatively the images with the numerics, thanks to our numerical reconstitution of CT-scans,
and we also fitted the tumor area. The lesion of this patient is interesting since it is confined in the
inner of the liver, and thus the tumor evolution was not constrained by mechanics of the organ. However,
in some cases, the tumor metastasis is close to the liver boundary. In such a case, there is no hope of
providing quantitative results on the spatial evolution of the lesion, but in the next subsection, we show
that the tumor area evolution can be well described.
5.1 Tumor area evolution for patient B
In this subsection, we focus on patient B, whose tumor evolution is quite different from patient A. Actually,
the clinical protocol of this patient was the following:
i) Patient B was treated in a first time with a specific tyrosine kinase inhibitor (imatinib), which
stabilizes the increase of the tumor area during more than 10 months before a relapse.
ii) The multi-targeted tyrosine kinase inhibitor sunitinib was started, but unlike for patient A, it was
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totally inefficient.
iii) A third treatment, was then delivered. Sorafenib is another multi-targeted tyrosine kinase inhibitor,
that has both antiangiogenic and cytotoxic effects. The tumor seemed to be sensitive to this drug
during several months until the treatment failure occurs.
Unfortunately, as illustrated by Figure 10g, the tumor evolution was so quick between the CT-scan at
Day 429 and the CT-scan at Day 845 that the metastasis has reached the boundary of the liver, and
thus with our model we have no hope to provide a numerical tumor growth that would be spatially in
accordance with the CT-scans, since mechanical effect of the liver membrane have to be accounted for.
Therefore we focus on the tumor area as given by the clinicians, the main challenge being to capture such
quick tumor growth.
(a) May 23, 2007 –
Day 0
(b) July 25, 2008 –
Day 429
(c) Sept 14, 2009 –
Day 845
(d) April 06, 2010 –
Day 1049
(e) Sept 28, 2010 –
Day 1224
(f) May 20, 2011 –
Day 1458
(g) Tumor area. Each point is the tumor area measured on CT-scans
and the line stands for our numerical results.
The letter refers to the CT-scans present on the left. The symbol ⊕
stands for heterogeneous tumor, • stands for rather homogeneous
tumor and ◦ stands for CT-scan on which it is difficult to detect the
heterogeneous aspect.
The value of parameters used in the numerical simulation are given in
Table 2.
Figure 10. Spatial evolution of the liver metastasis of patient B on a series of CT-scans. The small
round lesion in the top of Figure 10a is considered.
Since sunitinib is totally inefficient in this case, we consider that treatment T1 is delivered from Day 0
to Day 845, while treatment T2 consists in the sorefinib, delivered from Day 1049 to Day 1600. We find
8Do not confuse the metastasis with the gallbladder that are bigger on the first two CT-scans.
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parameters that make it possible to fit qualitatively the tumor area measured by the clinicians and our
numerical tumor area. These parameters are given in Table 2. The initial data has been chosen rotationaly
invariant, in accordance with the data of Figure 10a. As we can see, the tumor evolution is very stiff:
between Day 416 and Day 614 the tumor area has been multiplied by more than 9, and once sorafenib is
delivered the tumor area decreases from 4 500 mm2 to 2 850 mm2. We manage, at least qualitatively, to
obtain such behavior, even though the fit is not perfect.
We have also investigated the efficay of the treatment T1, as for patient A. It has been observed that
the progression free survival time TPFS, the doubling time Tdouble and the minimum area reached by the
lesion Amin have the same profile as the patient studied in the previous section. In particular, there exists
a threshold µth below which treatment has no effect on TPFS. Then an increase of the dose does not
improve the TPFS that reached, as for patient A, a plateau beyond µth. The doubling time Tdouble with
respect to µ1 is also not monotonic, contrary to Amin. Thus, as previously, beyond the threshold µth, the
tumor area decreases again, but the overall survival time of the patient is not increased.
5.2 Consistency of the model
(a) Imatinib from 119th day (b-c-d) Imatinib from 119th day until
867th day and sunitinib just after
(e-f-g) Imatinib from 119th day until
300th day and sunitinib just after
Figure 11. Different behaviors accounted for by the model.
Our model reproduces the clinical data give for patient A and patient B. Moreover, it is possible to
account for the following behaviors that have been reported by physicians as shown in the Figure 11 (see
Table 3 in the supplementary informations section, for the different values of the used parameters):
a) The metastasis is controlled by the treatment T1 (imatinib). In this case, there is no clinical need to
change the treatment.
b) The metastasis is controlled by the treatment T1 but then the tumor regrows. The treatment T2
(sunitinib or sorafenib) is then delivered successfully, and the tumor area is controlled.
c) The metastasis is controlled by the treatment T1 before a first relapse. Then, the treatment T2 is
efficient before a second relapse.
d) The metastasis is controlled by the treatment T1 before a first relapse. Then, the treatment T2 is
totally inefficient.
e) The treatment T1 is totally inefficient. Then, the treatment T2 is efficient and the tumor area is
controlled.
f) The treatment T1 is totally inefficient. Then, the treatment T2 is efficient before a relapse.
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g) The treatment T1 is totally inefficient. Then, the treatment T2 is totally inefficient. This profile
holds for a patient with a genetic mutation EXON, as reported by Andersson et al. [2], or Hirota et
al. [12].
6 Conclusion
In this paper, we have provided a patient-dependent model, based on PDEs, that describes the global
behavior of GIST metastasis to the liver during the different stages. We have presented the numerical
methods used to solve the PDE system and we introduced a new WENO5 type scheme, called twin-WENO5.
Then, this model has been numerically compared with clinical observations concerning patient A, who
have been treated successively by imatinib and sunitinib. As presented by Figure 1g, our model provides
results that are qualitatively in accordance with the clinical data. In particular, our model is able to
describe not only the evolution of the size of the lesion, but also its structure, as illustrated by Figure 1
and 2.
Interestingly, it has been reported by our simulations that a rim of proliferative cells appears on the
tumor boundary just before the relapse time. This seems to be corroborated in the CT-scans images by
an increase of the tumor heterogeneity, in the sense of grey-level, before the regrowth. The more the
metastases are heterogeneous, the quicker is the relapse. This result underlines the fact that the RECIST
criteria is not sufficient to evaluate the efficiency of a treatment.
We also investigated numerically the effect of the parameter µ1, linked to the efficacy of treatment T1.
We have shown that, according to the numerical model, increasing the value of µ1, which can be seen as
an increase in the drug delivery, does not provide better results in terms of progression free survival time
as reported by Figure 9.
It is worth noting that our model fits well with the data, but it is not predictive. Indeed, Figure 11b-c-d
shows that the knowledge of the first 400 days is not sufficient to determine uniquely the tumor growth.
This means that more precise data such as functional imaging could be necessary for a better analysis of
the inner structure of metastases.
In conclusion, we have provided a model that fits with the clinical CT-scans we had. The forthcoming
work will consist in adding more biological information that cannot be obtained from the CT-scans, in
order to provide a predictive model. Note that functional imaging data (TEP or MRI) or biopsies might
be crucial in enriching the present model.
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7 Supplementary informations
The set of parameters used to compute the numerical results given in Figure 11 of section 5.2 is presented
in Table 3.
RR n° 8642
26 G. Lefebvre et. al
Name a) b) c) d) e) f) g)
γ0 2.0e-2 2.03e-2 2.0e-2 1.97e-2 1.33e-2 1.33e-2 1.33e-2
γ1 6.67e-3 1.0e-2 1.0e-2 1.0e-2 1.0e-2 1.0e-2 1.0e-2
CS 10 10 10 10 10 10 10
Mth 2 2 2 2 2 2 2
δ 2.67e-2 3.0e-2 5.0e-2 3.0e-2 3.0e-2 3.0e-2 3.0e-2
ψ 3.33e-3 3.33e-3 3.33e-3 3.33e-3 3.33e-3 3.33e-3 3.33e-3
η 6.67e-2 6.67e-2 6.67e-2 6.67e-2 6.67e-2 6.67e-2 6.67e-2
α 1.11e-3 1.11e-3 1.11e-3 1.11e-3 1.11e-3 1.11e-3 1.11e-3
λ 2.0e-2 2.0e-2 2.0e-2 2.0e-2 2.0e-2 2.0e-2 2.0e-2
C0 3.33e-2 3.33e-2 3.33e-2 3.33e-2 3.33e-2 3.33e-2 3.33e-2
k 1 1 1 1 1 1 1
T1ini 119 119 119 119 119 119 119
T1end 3000 867 867 867 300 300 300
T2ini 3000 867 867 867 300 300 300
T2end 3000 1700 1298 1700 1700 1700 1700
µ1 8.33e-3 8.33e-3 8.33e-3 8.33e-3 8.33e-3 8.33e-3 8.33e-3
ν2 0.9 0.9 0.99 0.9 0.9 0.9 0.9
µ2 6.0e-4 6.0e-4 6.6e-4 6.0e-4 6.0e-4 6.0e-4 6.0e-4
εth 1.0e-2 1.0e-2 1.0e-2 1.0e-2 1.0e-2 1.0e-2 1.0e-2
Σini 0 4e-06 4e-06 2e-06 1 1 0.9
qini 0 0 4.5e-2 1 2e-07 3.0e-2 0.9
ξini 3.33e-3 3.33e-3 3.33e-3 3.33e-3 3.33e-3 3.33e-3 3.33e-3
L,D 6 6 6 6 6 6 6
Nx, Ny 120 120 120 120 120 120 120
r1, r2 0.62 0.62 0.62 0.62 0.62 0.62 0.62
e 0 0 0 0 0 0 0
β 0 0 0 0 0 0 0
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